[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fqn_0rn4R3PL1U6d1gg8VrtxlSTyDaK4VUYO0TUSNSj4":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":85,"rows":92},"Jules Bordet Institute",[4],101,false,29,5,16680,18,46,[14,17,20,23,25,27,30,32],{"name":15,"count":16},"Breast Cancer",21,{"name":18,"count":19},"Colorectal Cancer",4,{"name":21,"count":22},"Head and Neck Cancer",3,{"name":24,"count":22},"Peritoneal Carcinomatosis",{"name":26,"count":22},"Non Small Cell Lung Cancer",{"name":28,"count":29},"Ovarian Carcinoma",2,{"name":31,"count":29},"Invasive Breast Cancer",{"name":33,"count":29},"Prostate Cancer",[35,40,45,50,55,60,65,70,75,80],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT03616886","Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC","2025-03","Paclitaxel",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT03875573","Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +\u002F- Durvalumab, +\u002F- Oleclumab in Luminal B Breast Cancer:","2025-05-30","Durvalumab",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT06227338","ICG-fluorescence Imaging for Intraoperative Breast Cancer Margins Evaluation: a Dose-timing Study","2026-01-01","Indocyanine green",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT07143279","Testosterone Supplementation in Patients in Best Supportive Care: Impact on Quality of Life","2026-11","Sustanon 250",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT04503694","Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer","2026-12-31","Nivolumab 10 MG\u002FML Intravenous Solution",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT06150898","Ketorolac and Pregabalin Effects on breaSt Cancer (KePreSt)","2027-04-20","Ketorolac 10 Mg Oral",{"nctId":66,"briefTitle":67,"date":68,"intervention":69},"NCT04019548","Assessment of Swallowing Function and Quality of Life in Oropharyngeal Cancer Patients Treated by Chemo-radiotherapy","2027-11-01","Cisplatin",{"nctId":71,"briefTitle":72,"date":73,"intervention":74},"NCT06595563","HER2 Molecular Imaging With 89Zr-trastuzumab PET\u002FCT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer","2028-03","Trastuzumab emtansine",{"nctId":76,"briefTitle":77,"date":78,"intervention":79},"NCT06052332","Efficacy and Safety of Conventional Neoadjuvant Therapy Versus Total Neoadjuvant Therapy in Older Patients With Locally Advanced Rectal Cancer","2029-12","Adjuvant chemotherapy",{"nctId":81,"briefTitle":82,"date":83,"intervention":84},"NCT07474558","SCALp Cooling for pReventing aLopecia With nEw anTibody-drug Conjugates","2030-01","Antibody-Drug Conjugates",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,118,155,193,217,235,253,271,289,314,337,355,380,398,416,439,509,533,551,583,601,619,637,655,673,691,709,737,755,773,799,823,841,880,917,940,966,984,1007,1025,1043,1068,1092,1116,1146,1170,1199,1217,1235,1253,1271,1293,1311,1329,1354,1377,1403,1428,1452,1478,1496,1520,1544,1570,1588,1611,1646,1671,1697,1726,1744,1769,1794,1828,1846],{"intervention":69,"totalTrials":94,"cells":95},1,{"EARLY_PHASE1":96,"PHASE1":99,"PHASE2":101,"PHASE3":103,"PHASE4":114,"NA":116},{"trials":97,"activeCount":98},[],0,{"trials":100,"activeCount":98},[],{"trials":102,"activeCount":98},[],{"trials":104,"activeCount":94,"soonestReadout":68},[105],{"nctId":66,"briefTitle":67,"status":106,"phases":107,"primaryCompletion":68,"completion":108,"start":109,"enrollment":110,"conditions":111,"interventions":113},"RECRUITING",[89],"2030-05-01","2019-12-16",110,[112],"Oropharyngeal Cancer",[69],{"trials":115,"activeCount":98},[],{"trials":117,"activeCount":98},[],{"intervention":39,"totalTrials":29,"cells":119},{"EARLY_PHASE1":120,"PHASE1":122,"PHASE2":124,"PHASE3":149,"PHASE4":151,"NA":153},{"trials":121,"activeCount":98},[],{"trials":123,"activeCount":98},[],{"trials":125,"activeCount":94,"soonestReadout":38},[126,138],{"nctId":36,"briefTitle":37,"status":127,"phases":128,"primaryCompletion":38,"completion":129,"start":130,"enrollment":131,"conditions":132,"interventions":134},"ACTIVE_NOT_RECRUITING",[87,88],"2025-12","2018-12-28",129,[133],"Triple Negative Breast Cancer",[39,135,136,137],"Carboplatin","MEDI4736","MEDI9447",{"nctId":139,"briefTitle":140,"status":141,"phases":142,"primaryCompletion":143,"completion":143,"start":144,"enrollment":98,"conditions":145,"interventions":146},"NCT02053597","TRIal evalUating the Menstrual and Ovarian Function of Young Breast Cancer Patients Treated With a cycloPHosphamide-free Regimen","WITHDRAWN",[88],"2015-07","2014-10",[15],[147,148],"Doxorubicin","paclitaxel",{"trials":150,"activeCount":98},[],{"trials":152,"activeCount":98},[],{"trials":154,"activeCount":98},[],{"intervention":74,"totalTrials":29,"cells":156},{"EARLY_PHASE1":157,"PHASE1":159,"PHASE2":161,"PHASE3":187,"PHASE4":189,"NA":191},{"trials":158,"activeCount":98},[],{"trials":160,"activeCount":98},[],{"trials":162,"activeCount":94,"soonestReadout":73},[163,178],{"nctId":164,"briefTitle":165,"status":166,"phases":167,"primaryCompletion":168,"completion":168,"start":169,"enrollment":170,"conditions":171,"interventions":176},"NCT04675827","De-escalation Adjuvant Chemo in HER2+\u002FER-\u002Fnode-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade","TERMINATED",[88],"2024-11-26","2022-01-17",139,[172,173,174,175],"HER2-positive Breast Cancer","ER-Negative Breast Cancer","PR-Negative Breast Cancer","Node-negative Breast Cancer",[177,74],"Pertuzumab and tratuzumab fixed dose combination",{"nctId":71,"briefTitle":72,"status":106,"phases":179,"primaryCompletion":73,"completion":180,"start":181,"enrollment":182,"conditions":183,"interventions":186},[88],"2029-09","2026-06-30",87,[184,185],"HER2-positive Metastatic Breast Cancer","HER2-positive Advanced Breast Cancer",[74],{"trials":188,"activeCount":98},[],{"trials":190,"activeCount":98},[],{"trials":192,"activeCount":98},[],{"intervention":59,"totalTrials":94,"cells":194},{"EARLY_PHASE1":195,"PHASE1":197,"PHASE2":199,"PHASE3":211,"PHASE4":213,"NA":215},{"trials":196,"activeCount":98},[],{"trials":198,"activeCount":98},[],{"trials":200,"activeCount":94,"soonestReadout":58},[201],{"nctId":56,"briefTitle":57,"status":127,"phases":202,"primaryCompletion":58,"completion":203,"start":204,"enrollment":205,"conditions":206,"interventions":209},[88],"2032-12","2021-03-25",72,[207,208],"Rectal Cancer Stage II","Rectal Cancer Stage III",[59,210],"Regorafenib 30 MG Oral",{"trials":212,"activeCount":98},[],{"trials":214,"activeCount":98},[],{"trials":216,"activeCount":98},[],{"intervention":210,"totalTrials":94,"cells":218},{"EARLY_PHASE1":219,"PHASE1":221,"PHASE2":223,"PHASE3":229,"PHASE4":231,"NA":233},{"trials":220,"activeCount":98},[],{"trials":222,"activeCount":98},[],{"trials":224,"activeCount":94,"soonestReadout":58},[225],{"nctId":56,"briefTitle":57,"status":127,"phases":226,"primaryCompletion":58,"completion":203,"start":204,"enrollment":205,"conditions":227,"interventions":228},[88],[207,208],[59,210],{"trials":230,"activeCount":98},[],{"trials":232,"activeCount":98},[],{"trials":234,"activeCount":98},[],{"intervention":135,"totalTrials":94,"cells":236},{"EARLY_PHASE1":237,"PHASE1":239,"PHASE2":241,"PHASE3":247,"PHASE4":249,"NA":251},{"trials":238,"activeCount":98},[],{"trials":240,"activeCount":98},[],{"trials":242,"activeCount":94,"soonestReadout":38},[243],{"nctId":36,"briefTitle":37,"status":127,"phases":244,"primaryCompletion":38,"completion":129,"start":130,"enrollment":131,"conditions":245,"interventions":246},[87,88],[133],[39,135,136,137],{"trials":248,"activeCount":98},[],{"trials":250,"activeCount":98},[],{"trials":252,"activeCount":98},[],{"intervention":136,"totalTrials":94,"cells":254},{"EARLY_PHASE1":255,"PHASE1":257,"PHASE2":259,"PHASE3":265,"PHASE4":267,"NA":269},{"trials":256,"activeCount":98},[],{"trials":258,"activeCount":98},[],{"trials":260,"activeCount":94,"soonestReadout":38},[261],{"nctId":36,"briefTitle":37,"status":127,"phases":262,"primaryCompletion":38,"completion":129,"start":130,"enrollment":131,"conditions":263,"interventions":264},[87,88],[133],[39,135,136,137],{"trials":266,"activeCount":98},[],{"trials":268,"activeCount":98},[],{"trials":270,"activeCount":98},[],{"intervention":137,"totalTrials":94,"cells":272},{"EARLY_PHASE1":273,"PHASE1":275,"PHASE2":277,"PHASE3":283,"PHASE4":285,"NA":287},{"trials":274,"activeCount":98},[],{"trials":276,"activeCount":98},[],{"trials":278,"activeCount":94,"soonestReadout":38},[279],{"nctId":36,"briefTitle":37,"status":127,"phases":280,"primaryCompletion":38,"completion":129,"start":130,"enrollment":131,"conditions":281,"interventions":282},[87,88],[133],[39,135,136,137],{"trials":284,"activeCount":98},[],{"trials":286,"activeCount":98},[],{"trials":288,"activeCount":98},[],{"intervention":84,"totalTrials":94,"cells":290},{"EARLY_PHASE1":291,"PHASE1":293,"PHASE2":295,"PHASE3":308,"PHASE4":310,"NA":312},{"trials":292,"activeCount":98},[],{"trials":294,"activeCount":98},[],{"trials":296,"activeCount":94,"soonestReadout":83},[297],{"nctId":81,"briefTitle":82,"status":298,"phases":299,"primaryCompletion":83,"completion":300,"start":301,"enrollment":302,"conditions":303,"interventions":307},"NOT_YET_RECRUITING",[88],"2031-09","2026-09",102,[304,305,306],"Advanced or Metastatic Solid Tumour","Antibody-Drug Conjugate","Alopecia",[84],{"trials":309,"activeCount":98},[],{"trials":311,"activeCount":98},[],{"trials":313,"activeCount":98},[],{"intervention":44,"totalTrials":94,"cells":315},{"EARLY_PHASE1":316,"PHASE1":318,"PHASE2":320,"PHASE3":331,"PHASE4":333,"NA":335},{"trials":317,"activeCount":98},[],{"trials":319,"activeCount":98},[],{"trials":321,"activeCount":94,"soonestReadout":43},[322],{"nctId":41,"briefTitle":42,"status":127,"phases":323,"primaryCompletion":43,"completion":324,"start":325,"enrollment":326,"conditions":327,"interventions":329},[88],"2029-09-30","2019-11-06",147,[328],"Luminal B",[44,330],"Oleclumab",{"trials":332,"activeCount":98},[],{"trials":334,"activeCount":98},[],{"trials":336,"activeCount":98},[],{"intervention":330,"totalTrials":94,"cells":338},{"EARLY_PHASE1":339,"PHASE1":341,"PHASE2":343,"PHASE3":349,"PHASE4":351,"NA":353},{"trials":340,"activeCount":98},[],{"trials":342,"activeCount":98},[],{"trials":344,"activeCount":94,"soonestReadout":43},[345],{"nctId":41,"briefTitle":42,"status":127,"phases":346,"primaryCompletion":43,"completion":324,"start":325,"enrollment":326,"conditions":347,"interventions":348},[88],[328],[44,330],{"trials":350,"activeCount":98},[],{"trials":352,"activeCount":98},[],{"trials":354,"activeCount":98},[],{"intervention":64,"totalTrials":94,"cells":356},{"EARLY_PHASE1":357,"PHASE1":359,"PHASE2":361,"PHASE3":374,"PHASE4":376,"NA":378},{"trials":358,"activeCount":98},[],{"trials":360,"activeCount":98},[],{"trials":362,"activeCount":94,"soonestReadout":63},[363],{"nctId":61,"briefTitle":62,"status":106,"phases":364,"primaryCompletion":63,"completion":365,"start":366,"enrollment":367,"conditions":368,"interventions":371},[88],"2027-10","2025-05-12",112,[369,370],"Early-stage Breast Cancer","Estrogen-receptor-positive Breast Cancer",[64,372,373],"Pregabalin 75mg","Omeprazole 20mg",{"trials":375,"activeCount":98},[],{"trials":377,"activeCount":98},[],{"trials":379,"activeCount":98},[],{"intervention":372,"totalTrials":94,"cells":381},{"EARLY_PHASE1":382,"PHASE1":384,"PHASE2":386,"PHASE3":392,"PHASE4":394,"NA":396},{"trials":383,"activeCount":98},[],{"trials":385,"activeCount":98},[],{"trials":387,"activeCount":94,"soonestReadout":63},[388],{"nctId":61,"briefTitle":62,"status":106,"phases":389,"primaryCompletion":63,"completion":365,"start":366,"enrollment":367,"conditions":390,"interventions":391},[88],[369,370],[64,372,373],{"trials":393,"activeCount":98},[],{"trials":395,"activeCount":98},[],{"trials":397,"activeCount":98},[],{"intervention":373,"totalTrials":94,"cells":399},{"EARLY_PHASE1":400,"PHASE1":402,"PHASE2":404,"PHASE3":410,"PHASE4":412,"NA":414},{"trials":401,"activeCount":98},[],{"trials":403,"activeCount":98},[],{"trials":405,"activeCount":94,"soonestReadout":63},[406],{"nctId":61,"briefTitle":62,"status":106,"phases":407,"primaryCompletion":63,"completion":365,"start":366,"enrollment":367,"conditions":408,"interventions":409},[88],[369,370],[64,372,373],{"trials":411,"activeCount":98},[],{"trials":413,"activeCount":98},[],{"trials":415,"activeCount":98},[],{"intervention":54,"totalTrials":94,"cells":417},{"EARLY_PHASE1":418,"PHASE1":429,"PHASE2":431,"PHASE3":433,"PHASE4":435,"NA":437},{"trials":419,"activeCount":94,"soonestReadout":53},[420],{"nctId":51,"briefTitle":52,"status":106,"phases":421,"primaryCompletion":53,"completion":422,"start":423,"enrollment":424,"conditions":425,"interventions":428},[86],"2027-11","2026-02-11",20,[426,427],"Hypotestosteronism","Palliative Care",[54],{"trials":430,"activeCount":98},[],{"trials":432,"activeCount":98},[],{"trials":434,"activeCount":98},[],{"trials":436,"activeCount":98},[],{"trials":438,"activeCount":98},[],{"intervention":440,"totalTrials":441,"cells":442},"Indocyanine Green",7,{"EARLY_PHASE1":443,"PHASE1":445,"PHASE2":447,"PHASE3":497,"PHASE4":499,"NA":501},{"trials":444,"activeCount":98},[],{"trials":446,"activeCount":98},[],{"trials":448,"activeCount":98},[449,460,470,477,484,490],{"nctId":450,"briefTitle":451,"status":452,"phases":453,"primaryCompletion":454,"completion":454,"start":455,"enrollment":456,"conditions":457,"interventions":459},"NCT01993576","ICG Distribution Using NIF Imaging After IV Injection of ICG in Benign and Malignant Breast Cancer Tissue.","COMPLETED",[87,88],"2014-09","2013-01",10,[458],"Breast Cancer.",[440],{"nctId":461,"briefTitle":462,"status":463,"phases":464,"primaryCompletion":144,"completion":465,"start":466,"enrollment":467,"conditions":468,"interventions":469},"NCT02032498","Evaluation of Two Techniques for the SLN Detection in BC Patients","UNKNOWN",[88],"2014-12","2013-07",214,[15],[440],{"nctId":471,"briefTitle":472,"status":452,"phases":473,"primaryCompletion":144,"completion":144,"start":474,"enrollment":424,"conditions":475,"interventions":476},"NCT02027818","Study of the ICG Distribution in the Margins of Breast Cancer After Tumorectomy",[88],"2014-01",[15],[440],{"nctId":478,"briefTitle":479,"status":463,"phases":480,"primaryCompletion":144,"completion":144,"start":481,"enrollment":456,"conditions":482,"interventions":483},"NCT02027831","NIR Fluorescence Imaging During Neck Dissection in Head and Neck Cancer Patients After iv Injection of ICG",[88],"2013-12",[21],[440],{"nctId":485,"briefTitle":486,"status":463,"phases":487,"primaryCompletion":144,"completion":144,"start":481,"enrollment":424,"conditions":488,"interventions":489},"NCT02032563","Study of the ICG Distribution in Breast Tumours or in Axillary Lymph Nodes of Patients After Neoadjuvant Therapy",[88],[15],[440],{"nctId":491,"briefTitle":492,"status":452,"phases":493,"primaryCompletion":454,"completion":454,"start":494,"enrollment":456,"conditions":495,"interventions":496},"NCT02032485","Near-Infrared Imaging of Peritoneal Carcinomatosis From Colorectal Cancer",[88],"2013-03",[18,24],[440],{"trials":498,"activeCount":98},[],{"trials":500,"activeCount":98},[],{"trials":502,"activeCount":94,"soonestReadout":48},[503],{"nctId":46,"briefTitle":47,"status":106,"phases":504,"primaryCompletion":48,"completion":48,"start":505,"enrollment":506,"conditions":507,"interventions":508},[91],"2024-02-12",250,[15],[49],{"intervention":79,"totalTrials":94,"cells":510},{"EARLY_PHASE1":511,"PHASE1":513,"PHASE2":515,"PHASE3":517,"PHASE4":519,"NA":521},{"trials":512,"activeCount":98},[],{"trials":514,"activeCount":98},[],{"trials":516,"activeCount":98},[],{"trials":518,"activeCount":98},[],{"trials":520,"activeCount":98},[],{"trials":522,"activeCount":94,"soonestReadout":78},[523],{"nctId":76,"briefTitle":77,"status":106,"phases":524,"primaryCompletion":78,"completion":525,"start":526,"enrollment":527,"conditions":528,"interventions":531},[91],"2033-12","2024-02-07",230,[529,530],"Locally Advanced Rectal Cancer","Older People",[79,532],"Total neoadjuvant therapy",{"intervention":532,"totalTrials":94,"cells":534},{"EARLY_PHASE1":535,"PHASE1":537,"PHASE2":539,"PHASE3":541,"PHASE4":543,"NA":545},{"trials":536,"activeCount":98},[],{"trials":538,"activeCount":98},[],{"trials":540,"activeCount":98},[],{"trials":542,"activeCount":98},[],{"trials":544,"activeCount":98},[],{"trials":546,"activeCount":94,"soonestReadout":78},[547],{"nctId":76,"briefTitle":77,"status":106,"phases":548,"primaryCompletion":78,"completion":525,"start":526,"enrollment":527,"conditions":549,"interventions":550},[91],[529,530],[79,532],{"intervention":552,"totalTrials":94,"cells":553},"Spikevax",{"EARLY_PHASE1":554,"PHASE1":556,"PHASE2":558,"PHASE3":560,"PHASE4":562,"NA":581},{"trials":555,"activeCount":98},[],{"trials":557,"activeCount":98},[],{"trials":559,"activeCount":98},[],{"trials":561,"activeCount":98},[],{"trials":563,"activeCount":98},[564],{"nctId":565,"briefTitle":566,"status":166,"phases":567,"primaryCompletion":568,"completion":568,"start":569,"enrollment":570,"conditions":571,"interventions":573},"NCT05075538","COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2",[90],"2024-01-08","2021-12-01",152,[572],"Cancer",[552,574,575,576,577,578,579,580],"Comirnaty","Spikevax bivalent Original\u002FOmicron BA.1","Spikevax bivalent Original\u002FOmicron BA.4-5","Comirnaty Original\u002FOmicron BA.1","Comirnaty Original\u002FOmicron BA.4-5","Comirnaty Omicron XBB.1.5","Spikevax Omicron XBB.1.5",{"trials":582,"activeCount":98},[],{"intervention":574,"totalTrials":94,"cells":584},{"EARLY_PHASE1":585,"PHASE1":587,"PHASE2":589,"PHASE3":591,"PHASE4":593,"NA":599},{"trials":586,"activeCount":98},[],{"trials":588,"activeCount":98},[],{"trials":590,"activeCount":98},[],{"trials":592,"activeCount":98},[],{"trials":594,"activeCount":98},[595],{"nctId":565,"briefTitle":566,"status":166,"phases":596,"primaryCompletion":568,"completion":568,"start":569,"enrollment":570,"conditions":597,"interventions":598},[90],[572],[552,574,575,576,577,578,579,580],{"trials":600,"activeCount":98},[],{"intervention":575,"totalTrials":94,"cells":602},{"EARLY_PHASE1":603,"PHASE1":605,"PHASE2":607,"PHASE3":609,"PHASE4":611,"NA":617},{"trials":604,"activeCount":98},[],{"trials":606,"activeCount":98},[],{"trials":608,"activeCount":98},[],{"trials":610,"activeCount":98},[],{"trials":612,"activeCount":98},[613],{"nctId":565,"briefTitle":566,"status":166,"phases":614,"primaryCompletion":568,"completion":568,"start":569,"enrollment":570,"conditions":615,"interventions":616},[90],[572],[552,574,575,576,577,578,579,580],{"trials":618,"activeCount":98},[],{"intervention":576,"totalTrials":94,"cells":620},{"EARLY_PHASE1":621,"PHASE1":623,"PHASE2":625,"PHASE3":627,"PHASE4":629,"NA":635},{"trials":622,"activeCount":98},[],{"trials":624,"activeCount":98},[],{"trials":626,"activeCount":98},[],{"trials":628,"activeCount":98},[],{"trials":630,"activeCount":98},[631],{"nctId":565,"briefTitle":566,"status":166,"phases":632,"primaryCompletion":568,"completion":568,"start":569,"enrollment":570,"conditions":633,"interventions":634},[90],[572],[552,574,575,576,577,578,579,580],{"trials":636,"activeCount":98},[],{"intervention":577,"totalTrials":94,"cells":638},{"EARLY_PHASE1":639,"PHASE1":641,"PHASE2":643,"PHASE3":645,"PHASE4":647,"NA":653},{"trials":640,"activeCount":98},[],{"trials":642,"activeCount":98},[],{"trials":644,"activeCount":98},[],{"trials":646,"activeCount":98},[],{"trials":648,"activeCount":98},[649],{"nctId":565,"briefTitle":566,"status":166,"phases":650,"primaryCompletion":568,"completion":568,"start":569,"enrollment":570,"conditions":651,"interventions":652},[90],[572],[552,574,575,576,577,578,579,580],{"trials":654,"activeCount":98},[],{"intervention":578,"totalTrials":94,"cells":656},{"EARLY_PHASE1":657,"PHASE1":659,"PHASE2":661,"PHASE3":663,"PHASE4":665,"NA":671},{"trials":658,"activeCount":98},[],{"trials":660,"activeCount":98},[],{"trials":662,"activeCount":98},[],{"trials":664,"activeCount":98},[],{"trials":666,"activeCount":98},[667],{"nctId":565,"briefTitle":566,"status":166,"phases":668,"primaryCompletion":568,"completion":568,"start":569,"enrollment":570,"conditions":669,"interventions":670},[90],[572],[552,574,575,576,577,578,579,580],{"trials":672,"activeCount":98},[],{"intervention":579,"totalTrials":94,"cells":674},{"EARLY_PHASE1":675,"PHASE1":677,"PHASE2":679,"PHASE3":681,"PHASE4":683,"NA":689},{"trials":676,"activeCount":98},[],{"trials":678,"activeCount":98},[],{"trials":680,"activeCount":98},[],{"trials":682,"activeCount":98},[],{"trials":684,"activeCount":98},[685],{"nctId":565,"briefTitle":566,"status":166,"phases":686,"primaryCompletion":568,"completion":568,"start":569,"enrollment":570,"conditions":687,"interventions":688},[90],[572],[552,574,575,576,577,578,579,580],{"trials":690,"activeCount":98},[],{"intervention":580,"totalTrials":94,"cells":692},{"EARLY_PHASE1":693,"PHASE1":695,"PHASE2":697,"PHASE3":699,"PHASE4":701,"NA":707},{"trials":694,"activeCount":98},[],{"trials":696,"activeCount":98},[],{"trials":698,"activeCount":98},[],{"trials":700,"activeCount":98},[],{"trials":702,"activeCount":98},[703],{"nctId":565,"briefTitle":566,"status":166,"phases":704,"primaryCompletion":568,"completion":568,"start":569,"enrollment":570,"conditions":705,"interventions":706},[90],[572],[552,574,575,576,577,578,579,580],{"trials":708,"activeCount":98},[],{"intervention":710,"totalTrials":94,"cells":711},"Ropivacaine",{"EARLY_PHASE1":712,"PHASE1":714,"PHASE2":716,"PHASE3":718,"PHASE4":733,"NA":735},{"trials":713,"activeCount":98},[],{"trials":715,"activeCount":98},[],{"trials":717,"activeCount":98},[],{"trials":719,"activeCount":98},[720],{"nctId":721,"briefTitle":722,"status":452,"phases":723,"primaryCompletion":724,"completion":725,"start":726,"enrollment":727,"conditions":728,"interventions":730},"NCT02655965","Double-blind Study to Assess effectIveness of Pectoral Nerves Block After Breast Surgery on Piritramide Consumption",[89],"2019-11","2021-01-20","2016-05",54,[729],"Locoregional Analgesia in Breast Surgery",[710,731,732],"Clonidine","Sodium Chloride",{"trials":734,"activeCount":98},[],{"trials":736,"activeCount":98},[],{"intervention":731,"totalTrials":94,"cells":738},{"EARLY_PHASE1":739,"PHASE1":741,"PHASE2":743,"PHASE3":745,"PHASE4":751,"NA":753},{"trials":740,"activeCount":98},[],{"trials":742,"activeCount":98},[],{"trials":744,"activeCount":98},[],{"trials":746,"activeCount":98},[747],{"nctId":721,"briefTitle":722,"status":452,"phases":748,"primaryCompletion":724,"completion":725,"start":726,"enrollment":727,"conditions":749,"interventions":750},[89],[729],[710,731,732],{"trials":752,"activeCount":98},[],{"trials":754,"activeCount":98},[],{"intervention":732,"totalTrials":94,"cells":756},{"EARLY_PHASE1":757,"PHASE1":759,"PHASE2":761,"PHASE3":763,"PHASE4":769,"NA":771},{"trials":758,"activeCount":98},[],{"trials":760,"activeCount":98},[],{"trials":762,"activeCount":98},[],{"trials":764,"activeCount":98},[765],{"nctId":721,"briefTitle":722,"status":452,"phases":766,"primaryCompletion":724,"completion":725,"start":726,"enrollment":727,"conditions":767,"interventions":768},[89],[729],[710,731,732],{"trials":770,"activeCount":98},[],{"trials":772,"activeCount":98},[],{"intervention":774,"totalTrials":94,"cells":775},"Intravenous injection of 177Lu-octreotate",{"EARLY_PHASE1":776,"PHASE1":778,"PHASE2":780,"PHASE3":782,"PHASE4":795,"NA":797},{"trials":777,"activeCount":98},[],{"trials":779,"activeCount":98},[],{"trials":781,"activeCount":98},[],{"trials":783,"activeCount":98},[784],{"nctId":785,"briefTitle":786,"status":452,"phases":787,"primaryCompletion":788,"completion":789,"start":790,"enrollment":791,"conditions":792,"interventions":794},"NCT01842165","177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs",[89],"2022-01-14","2022-09-19","2013-05",37,[793],"Gastroenteropancreatic Neuroendocrine Tumors",[774],{"trials":796,"activeCount":98},[],{"trials":798,"activeCount":98},[],{"intervention":800,"totalTrials":94,"cells":801},"Interferon alpha-2b",{"EARLY_PHASE1":802,"PHASE1":804,"PHASE2":806,"PHASE3":808,"PHASE4":819,"NA":821},{"trials":803,"activeCount":98},[],{"trials":805,"activeCount":98},[],{"trials":807,"activeCount":98},[],{"trials":809,"activeCount":98},[810],{"nctId":811,"briefTitle":812,"status":141,"phases":813,"primaryCompletion":814,"completion":814,"start":465,"enrollment":98,"conditions":815,"interventions":817},"NCT01860742","Randomized Phase III of PRRT Versus Interferon",[89],"2016-10",[816],"Gastro-intestinal Neuroendocrine Tumors",[800,818],"177Lu-DOTATATE",{"trials":820,"activeCount":98},[],{"trials":822,"activeCount":98},[],{"intervention":818,"totalTrials":94,"cells":824},{"EARLY_PHASE1":825,"PHASE1":827,"PHASE2":829,"PHASE3":831,"PHASE4":837,"NA":839},{"trials":826,"activeCount":98},[],{"trials":828,"activeCount":98},[],{"trials":830,"activeCount":98},[],{"trials":832,"activeCount":98},[833],{"nctId":811,"briefTitle":812,"status":141,"phases":834,"primaryCompletion":814,"completion":814,"start":465,"enrollment":98,"conditions":835,"interventions":836},[89],[816],[800,818],{"trials":838,"activeCount":98},[],{"trials":840,"activeCount":98},[],{"intervention":842,"totalTrials":29,"cells":843},"Oxaliplatin",{"EARLY_PHASE1":844,"PHASE1":846,"PHASE2":848,"PHASE3":874,"PHASE4":876,"NA":878},{"trials":845,"activeCount":98},[],{"trials":847,"activeCount":98},[],{"trials":849,"activeCount":98},[850,861],{"nctId":851,"briefTitle":852,"status":452,"phases":853,"primaryCompletion":854,"completion":854,"start":855,"enrollment":856,"conditions":857,"interventions":859},"NCT01481701","A Trial Evaluating Efficacy and Safety of Oxaliplatin With 5-Fluorouracil in Patients With Recurrent Ovarian Carcinoma",[88],"2014-05","2008-10",90,[28,858],"Relapse",[842,860],"oxaliplatin",{"nctId":862,"briefTitle":863,"status":141,"phases":864,"primaryCompletion":865,"completion":865,"start":866,"enrollment":98,"conditions":867,"interventions":871},"NCT03307941","Assessment of Metabolic & Path Response w\u002F RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph Jction CA",[87,88],"2017-12-11","2017-07-20",[868,869,870],"Adenocarcinoma of the Esophagus","Adenocarcinoma of the Gastroesophageal Junction","Squamous Cell Carcinoma of the Esophagus",[872,842,873],"Monalizumab","5-Fluorouracil",{"trials":875,"activeCount":98},[],{"trials":877,"activeCount":98},[],{"trials":879,"activeCount":98},[],{"intervention":881,"totalTrials":29,"cells":882},"Letrozole",{"EARLY_PHASE1":883,"PHASE1":885,"PHASE2":887,"PHASE3":911,"PHASE4":913,"NA":915},{"trials":884,"activeCount":98},[],{"trials":886,"activeCount":98},[],{"trials":888,"activeCount":98},[889,903],{"nctId":890,"briefTitle":891,"status":463,"phases":892,"primaryCompletion":893,"completion":893,"start":894,"enrollment":895,"conditions":896,"interventions":900},"NCT04551495","Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE)",[88],"2025-01","2021-01-14",65,[897,898,899],"Invasive Lobular Breast Carcinoma","ER+ Breast Cancer","HER2-negative Breast Cancer",[901,881,902],"Entrectinib","Goserelin",{"nctId":904,"briefTitle":905,"status":452,"phases":906,"primaryCompletion":465,"completion":465,"start":907,"enrollment":908,"conditions":909,"interventions":910},"NCT00199134","FRAGRANCE Part A Safety: Study to Find a Genetic Signature of de Novo Resistance to Letrozole",[88],"2004-11",49,[15],[881],{"trials":912,"activeCount":98},[],{"trials":914,"activeCount":98},[],{"trials":916,"activeCount":98},[],{"intervention":918,"totalTrials":94,"cells":919},"68Ga-(HBED-CC)-PSMA",{"EARLY_PHASE1":920,"PHASE1":922,"PHASE2":924,"PHASE3":934,"PHASE4":936,"NA":938},{"trials":921,"activeCount":98},[],{"trials":923,"activeCount":98},[],{"trials":925,"activeCount":98},[926],{"nctId":927,"briefTitle":928,"status":141,"phases":929,"primaryCompletion":930,"completion":930,"start":814,"enrollment":98,"conditions":931,"interventions":933},"NCT02810886","Prospective Evaluation of 68Ga-PSMA PET-CT for Recurrence Detection of Prostate Cancer and Its Impact on Patient Management",[88],"2017-01-20",[932],"Prostate Cancers",[918],{"trials":935,"activeCount":98},[],{"trials":937,"activeCount":98},[],{"trials":939,"activeCount":98},[],{"intervention":941,"totalTrials":94,"cells":942},"Adjuvant capecitabine",{"EARLY_PHASE1":943,"PHASE1":945,"PHASE2":947,"PHASE3":960,"PHASE4":962,"NA":964},{"trials":944,"activeCount":98},[],{"trials":946,"activeCount":98},[],{"trials":948,"activeCount":98},[949],{"nctId":950,"briefTitle":951,"status":452,"phases":952,"primaryCompletion":953,"completion":953,"start":954,"enrollment":955,"conditions":956,"interventions":958},"NCT00263705","Adjuvant Capecitabine in Elderly Patients With Breast Cancer: a Phase II Study",[88],"2009-08","2003-01",43,[957,15],"Elderly Patients",[941,959],"capecitabine in aduvant setting",{"trials":961,"activeCount":98},[],{"trials":963,"activeCount":98},[],{"trials":965,"activeCount":98},[],{"intervention":959,"totalTrials":94,"cells":967},{"EARLY_PHASE1":968,"PHASE1":970,"PHASE2":972,"PHASE3":978,"PHASE4":980,"NA":982},{"trials":969,"activeCount":98},[],{"trials":971,"activeCount":98},[],{"trials":973,"activeCount":98},[974],{"nctId":950,"briefTitle":951,"status":452,"phases":975,"primaryCompletion":953,"completion":953,"start":954,"enrollment":955,"conditions":976,"interventions":977},[88],[957,15],[941,959],{"trials":979,"activeCount":98},[],{"trials":981,"activeCount":98},[],{"trials":983,"activeCount":98},[],{"intervention":985,"totalTrials":94,"cells":986},"Neratinib",{"EARLY_PHASE1":987,"PHASE1":989,"PHASE2":991,"PHASE3":1001,"PHASE4":1003,"NA":1005},{"trials":988,"activeCount":98},[],{"trials":990,"activeCount":98},[],{"trials":992,"activeCount":98},[993],{"nctId":994,"briefTitle":995,"status":141,"phases":996,"primaryCompletion":997,"completion":997,"start":997,"enrollment":98,"conditions":998,"interventions":1000},"NCT04856475","Evaluation of Neratinib for Treatment and Prevention of Subsequent CNS Event(s) in Patients With Brain Metastasis of Advanced HER2 Positive Breast Cancer",[88],"2021-11-24",[15,999],"Brain Metastases",[985],{"trials":1002,"activeCount":98},[],{"trials":1004,"activeCount":98},[],{"trials":1006,"activeCount":98},[],{"intervention":872,"totalTrials":94,"cells":1008},{"EARLY_PHASE1":1009,"PHASE1":1011,"PHASE2":1013,"PHASE3":1019,"PHASE4":1021,"NA":1023},{"trials":1010,"activeCount":98},[],{"trials":1012,"activeCount":98},[],{"trials":1014,"activeCount":98},[1015],{"nctId":862,"briefTitle":863,"status":141,"phases":1016,"primaryCompletion":865,"completion":865,"start":866,"enrollment":98,"conditions":1017,"interventions":1018},[87,88],[868,869,870],[872,842,873],{"trials":1020,"activeCount":98},[],{"trials":1022,"activeCount":98},[],{"trials":1024,"activeCount":98},[],{"intervention":873,"totalTrials":94,"cells":1026},{"EARLY_PHASE1":1027,"PHASE1":1029,"PHASE2":1031,"PHASE3":1037,"PHASE4":1039,"NA":1041},{"trials":1028,"activeCount":98},[],{"trials":1030,"activeCount":98},[],{"trials":1032,"activeCount":98},[1033],{"nctId":862,"briefTitle":863,"status":141,"phases":1034,"primaryCompletion":865,"completion":865,"start":866,"enrollment":98,"conditions":1035,"interventions":1036},[87,88],[868,869,870],[872,842,873],{"trials":1038,"activeCount":98},[],{"trials":1040,"activeCount":98},[],{"trials":1042,"activeCount":98},[],{"intervention":1044,"totalTrials":94,"cells":1045},"BAY 43-9006",{"EARLY_PHASE1":1046,"PHASE1":1048,"PHASE2":1050,"PHASE3":1062,"PHASE4":1064,"NA":1066},{"trials":1047,"activeCount":98},[],{"trials":1049,"activeCount":98},[],{"trials":1051,"activeCount":98},[1052],{"nctId":1053,"briefTitle":1054,"status":452,"phases":1055,"primaryCompletion":1056,"completion":1056,"start":1057,"enrollment":1058,"conditions":1059,"interventions":1061},"NCT00199160","Efficacy and Activity of BAY 43-9006 in Patients With Recurrent and\u002For Metastatic Head and Neck Cancer",[88],"2010-06","2005-04",60,[1060],"Head and Neck Neoplasms",[1044],{"trials":1063,"activeCount":98},[],{"trials":1065,"activeCount":98},[],{"trials":1067,"activeCount":98},[],{"intervention":1069,"totalTrials":94,"cells":1070},"PF-03084014",{"EARLY_PHASE1":1071,"PHASE1":1073,"PHASE2":1075,"PHASE3":1086,"PHASE4":1088,"NA":1090},{"trials":1072,"activeCount":98},[],{"trials":1074,"activeCount":98},[],{"trials":1076,"activeCount":98},[1077],{"nctId":1078,"briefTitle":1079,"status":141,"phases":1080,"primaryCompletion":1081,"completion":1082,"start":1083,"enrollment":98,"conditions":1084,"interventions":1085},"NCT02338531","Biomarker Research Study for PF-03084014 in cHEmoresistant Triple-negative Breast cAncer",[88],"2018-09","2018-12","2015-06",[15],[1069],{"trials":1087,"activeCount":98},[],{"trials":1089,"activeCount":98},[],{"trials":1091,"activeCount":98},[],{"intervention":1093,"totalTrials":94,"cells":1094},"EndoTAG-1",{"EARLY_PHASE1":1095,"PHASE1":1097,"PHASE2":1099,"PHASE3":1110,"PHASE4":1112,"NA":1114},{"trials":1096,"activeCount":98},[],{"trials":1098,"activeCount":98},[],{"trials":1100,"activeCount":98},[1101],{"nctId":1102,"briefTitle":1103,"status":452,"phases":1104,"primaryCompletion":1105,"completion":1106,"start":1107,"enrollment":11,"conditions":1108,"interventions":1109},"NCT01537536","Trial of Neoadjuvant EndoTAG-1 in Combination With Paclitaxel in HER2-negative Breast Cancer",[88],"2012-09","2012-11","2011-11",[15],[1093],{"trials":1111,"activeCount":98},[],{"trials":1113,"activeCount":98},[],{"trials":1115,"activeCount":98},[],{"intervention":1117,"totalTrials":94,"cells":1118},"Abemaciclib",{"EARLY_PHASE1":1119,"PHASE1":1121,"PHASE2":1123,"PHASE3":1140,"PHASE4":1142,"NA":1144},{"trials":1120,"activeCount":98},[],{"trials":1122,"activeCount":98},[],{"trials":1124,"activeCount":98},[1125],{"nctId":1126,"briefTitle":1127,"status":452,"phases":1128,"primaryCompletion":1129,"completion":1130,"start":1131,"enrollment":1132,"conditions":1133,"interventions":1139},"NCT03339843","Multiorgan Metabolic Imaging Response Assessment of Abemaciclib",[88],"2021-11-12","2023-12-20","2018-12-19",85,[1134,1135,1136,1137,1138],"Esophageal Adenocarcinoma","Esophagus SCC","Cholangiocarcinoma","Urothelial\u002FBladder Cancer, Nos","Endometrial Cancer",[1117],{"trials":1141,"activeCount":98},[],{"trials":1143,"activeCount":98},[],{"trials":1145,"activeCount":98},[],{"intervention":1147,"totalTrials":94,"cells":1148},"Epirubicin",{"EARLY_PHASE1":1149,"PHASE1":1151,"PHASE2":1153,"PHASE3":1164,"PHASE4":1166,"NA":1168},{"trials":1150,"activeCount":98},[],{"trials":1152,"activeCount":98},[],{"trials":1154,"activeCount":98},[1155],{"nctId":1156,"briefTitle":1157,"status":166,"phases":1158,"primaryCompletion":1159,"completion":1160,"start":954,"enrollment":1161,"conditions":1162,"interventions":1163},"NCT00162812","Topoisomerase II Alpha Gene Amplification and Protein Overexpression Predicting Efficacy of Epirubicin",[88],"2008-12","2009-04",338,[15],[1147],{"trials":1165,"activeCount":98},[],{"trials":1167,"activeCount":98},[],{"trials":1169,"activeCount":98},[],{"intervention":1171,"totalTrials":94,"cells":1172},"Avelumab",{"EARLY_PHASE1":1173,"PHASE1":1175,"PHASE2":1177,"PHASE3":1193,"PHASE4":1195,"NA":1197},{"trials":1174,"activeCount":98},[],{"trials":1176,"activeCount":98},[],{"trials":1178,"activeCount":98},[1179],{"nctId":1180,"briefTitle":1181,"status":452,"phases":1182,"primaryCompletion":1183,"completion":1184,"start":1185,"enrollment":1186,"conditions":1187,"interventions":1189},"NCT03674424","Avelumab as Neoadjuvant Therapy in Subjects With Urothelial Muscle Invasive Bladder Cancers (AURA Trial)",[88],"2021-12-07","2025-01-30","2018-06-01",137,[1188],"Non-metastatic Muscle Invasive Bladder Cancer",[1171,1190,1191,1192],"CG","DD-MVAC","PG",{"trials":1194,"activeCount":98},[],{"trials":1196,"activeCount":98},[],{"trials":1198,"activeCount":98},[],{"intervention":1190,"totalTrials":94,"cells":1200},{"EARLY_PHASE1":1201,"PHASE1":1203,"PHASE2":1205,"PHASE3":1211,"PHASE4":1213,"NA":1215},{"trials":1202,"activeCount":98},[],{"trials":1204,"activeCount":98},[],{"trials":1206,"activeCount":98},[1207],{"nctId":1180,"briefTitle":1181,"status":452,"phases":1208,"primaryCompletion":1183,"completion":1184,"start":1185,"enrollment":1186,"conditions":1209,"interventions":1210},[88],[1188],[1171,1190,1191,1192],{"trials":1212,"activeCount":98},[],{"trials":1214,"activeCount":98},[],{"trials":1216,"activeCount":98},[],{"intervention":1191,"totalTrials":94,"cells":1218},{"EARLY_PHASE1":1219,"PHASE1":1221,"PHASE2":1223,"PHASE3":1229,"PHASE4":1231,"NA":1233},{"trials":1220,"activeCount":98},[],{"trials":1222,"activeCount":98},[],{"trials":1224,"activeCount":98},[1225],{"nctId":1180,"briefTitle":1181,"status":452,"phases":1226,"primaryCompletion":1183,"completion":1184,"start":1185,"enrollment":1186,"conditions":1227,"interventions":1228},[88],[1188],[1171,1190,1191,1192],{"trials":1230,"activeCount":98},[],{"trials":1232,"activeCount":98},[],{"trials":1234,"activeCount":98},[],{"intervention":1192,"totalTrials":94,"cells":1236},{"EARLY_PHASE1":1237,"PHASE1":1239,"PHASE2":1241,"PHASE3":1247,"PHASE4":1249,"NA":1251},{"trials":1238,"activeCount":98},[],{"trials":1240,"activeCount":98},[],{"trials":1242,"activeCount":98},[1243],{"nctId":1180,"briefTitle":1181,"status":452,"phases":1244,"primaryCompletion":1183,"completion":1184,"start":1185,"enrollment":1186,"conditions":1245,"interventions":1246},[88],[1188],[1171,1190,1191,1192],{"trials":1248,"activeCount":98},[],{"trials":1250,"activeCount":98},[],{"trials":1252,"activeCount":98},[],{"intervention":177,"totalTrials":94,"cells":1254},{"EARLY_PHASE1":1255,"PHASE1":1257,"PHASE2":1259,"PHASE3":1265,"PHASE4":1267,"NA":1269},{"trials":1256,"activeCount":98},[],{"trials":1258,"activeCount":98},[],{"trials":1260,"activeCount":98},[1261],{"nctId":164,"briefTitle":165,"status":166,"phases":1262,"primaryCompletion":168,"completion":168,"start":169,"enrollment":170,"conditions":1263,"interventions":1264},[88],[172,173,174,175],[177,74],{"trials":1266,"activeCount":98},[],{"trials":1268,"activeCount":98},[],{"trials":1270,"activeCount":98},[],{"intervention":1272,"totalTrials":94,"cells":1273},"iv injection of ICG",{"EARLY_PHASE1":1274,"PHASE1":1276,"PHASE2":1278,"PHASE3":1287,"PHASE4":1289,"NA":1291},{"trials":1275,"activeCount":98},[],{"trials":1277,"activeCount":98},[],{"trials":1279,"activeCount":98},[1280],{"nctId":1281,"briefTitle":1282,"status":452,"phases":1283,"primaryCompletion":144,"completion":144,"start":494,"enrollment":456,"conditions":1284,"interventions":1286},"NCT01834469","Imaging of Peritoneal Carcinomatosis From Ovarian Carcinoma Patients",[87,88],[1285,24],"Ovarian Cancer",[1272],{"trials":1288,"activeCount":98},[],{"trials":1290,"activeCount":98},[],{"trials":1292,"activeCount":98},[],{"intervention":901,"totalTrials":94,"cells":1294},{"EARLY_PHASE1":1295,"PHASE1":1297,"PHASE2":1299,"PHASE3":1305,"PHASE4":1307,"NA":1309},{"trials":1296,"activeCount":98},[],{"trials":1298,"activeCount":98},[],{"trials":1300,"activeCount":98},[1301],{"nctId":890,"briefTitle":891,"status":463,"phases":1302,"primaryCompletion":893,"completion":893,"start":894,"enrollment":895,"conditions":1303,"interventions":1304},[88],[897,898,899],[901,881,902],{"trials":1306,"activeCount":98},[],{"trials":1308,"activeCount":98},[],{"trials":1310,"activeCount":98},[],{"intervention":902,"totalTrials":94,"cells":1312},{"EARLY_PHASE1":1313,"PHASE1":1315,"PHASE2":1317,"PHASE3":1323,"PHASE4":1325,"NA":1327},{"trials":1314,"activeCount":98},[],{"trials":1316,"activeCount":98},[],{"trials":1318,"activeCount":98},[1319],{"nctId":890,"briefTitle":891,"status":463,"phases":1320,"primaryCompletion":893,"completion":893,"start":894,"enrollment":895,"conditions":1321,"interventions":1322},[88],[897,898,899],[901,881,902],{"trials":1324,"activeCount":98},[],{"trials":1326,"activeCount":98},[],{"trials":1328,"activeCount":98},[],{"intervention":1330,"totalTrials":94,"cells":1331},"Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic",{"EARLY_PHASE1":1332,"PHASE1":1334,"PHASE2":1336,"PHASE3":1348,"PHASE4":1350,"NA":1352},{"trials":1333,"activeCount":98},[],{"trials":1335,"activeCount":98},[],{"trials":1337,"activeCount":98},[1338],{"nctId":1339,"briefTitle":1340,"status":463,"phases":1341,"primaryCompletion":481,"completion":465,"start":1342,"enrollment":424,"conditions":1343,"interventions":1347},"NCT01513109","Safety and Immunogenicity of Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic Combined With Infusion of Treg Depleted T Cells for Adult WT1 Acute Myeloid Leukemia",[87,88],"2011-12",[1344,1345,1346],"Acute Myelogenous Leukemia","Myeloid Leukemia in Remission","Effects of Immunotherapy",[1330],{"trials":1349,"activeCount":98},[],{"trials":1351,"activeCount":98},[],{"trials":1353,"activeCount":98},[],{"intervention":1355,"totalTrials":94,"cells":1356},"epirubicin, cyclophosphamide, docetaxel",{"EARLY_PHASE1":1357,"PHASE1":1359,"PHASE2":1361,"PHASE3":1371,"PHASE4":1373,"NA":1375},{"trials":1358,"activeCount":98},[],{"trials":1360,"activeCount":98},[],{"trials":1362,"activeCount":98},[1363],{"nctId":1364,"briefTitle":1365,"status":166,"phases":1366,"primaryCompletion":494,"completion":1367,"start":1368,"enrollment":29,"conditions":1369,"interventions":1370},"NCT01301040","Early Cardiac Toxicity of Adjuvant CT in Elderly BC.",[88],"2016-03","2011-03",[15],[1355],{"trials":1372,"activeCount":98},[],{"trials":1374,"activeCount":98},[],{"trials":1376,"activeCount":98},[],{"intervention":1378,"totalTrials":94,"cells":1379},"regorafenib",{"EARLY_PHASE1":1380,"PHASE1":1382,"PHASE2":1384,"PHASE3":1397,"PHASE4":1399,"NA":1401},{"trials":1381,"activeCount":98},[],{"trials":1383,"activeCount":98},[],{"trials":1385,"activeCount":98},[1386],{"nctId":1387,"briefTitle":1388,"status":452,"phases":1389,"primaryCompletion":1390,"completion":1391,"start":1392,"enrollment":1393,"conditions":1394,"interventions":1396},"NCT01929616","Regorafenib Assessment in Refractory Advanced Colorectal Cancer(RegARd-C)",[88],"2016-05-13","2019-06-17","2013-08",141,[1395],"Advanced Chemorefractory Colorectal Adenocarcinoma",[1378],{"trials":1398,"activeCount":98},[],{"trials":1400,"activeCount":98},[],{"trials":1402,"activeCount":98},[],{"intervention":1404,"totalTrials":94,"cells":1405},"T-DM1",{"EARLY_PHASE1":1406,"PHASE1":1408,"PHASE2":1410,"PHASE3":1422,"PHASE4":1424,"NA":1426},{"trials":1407,"activeCount":98},[],{"trials":1409,"activeCount":98},[],{"trials":1411,"activeCount":98},[1412],{"nctId":1413,"briefTitle":1414,"status":452,"phases":1415,"primaryCompletion":1416,"completion":1417,"start":1418,"enrollment":856,"conditions":1419,"interventions":1421},"NCT01565200","HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1",[88],"2017-07","2022-12","2012-05",[1420],"HER-2 Positive Breast Cancer",[1404],{"trials":1423,"activeCount":98},[],{"trials":1425,"activeCount":98},[],{"trials":1427,"activeCount":98},[],{"intervention":1429,"totalTrials":94,"cells":1430},"Denosumab",{"EARLY_PHASE1":1431,"PHASE1":1433,"PHASE2":1435,"PHASE3":1446,"PHASE4":1448,"NA":1450},{"trials":1432,"activeCount":98},[],{"trials":1434,"activeCount":98},[],{"trials":1436,"activeCount":98},[1437],{"nctId":1438,"briefTitle":1439,"status":166,"phases":1440,"primaryCompletion":1441,"completion":1441,"start":466,"enrollment":1442,"conditions":1443,"interventions":1445},"NCT01864798","A Study to Evaluate Denosumab in Young Patients With Primary Breast Cancer",[88],"2017-01",27,[1444],"Breast Neoplasms",[1429],{"trials":1447,"activeCount":98},[],{"trials":1449,"activeCount":98},[],{"trials":1451,"activeCount":98},[],{"intervention":1453,"totalTrials":94,"cells":1454},"Everolimus",{"EARLY_PHASE1":1455,"PHASE1":1457,"PHASE2":1459,"PHASE3":1472,"PHASE4":1474,"NA":1476},{"trials":1456,"activeCount":98},[],{"trials":1458,"activeCount":98},[],{"trials":1460,"activeCount":98},[1461],{"nctId":1462,"briefTitle":1463,"status":452,"phases":1464,"primaryCompletion":1465,"completion":1466,"start":1467,"enrollment":1468,"conditions":1469,"interventions":1470},"NCT02028364","Pet Imaging as a Biomarker in Hormone Refractory postmenopausaL Women",[88],"2021-07-06","2021-08-09","2014-01-12",55,[15],[1453,1471],"Exemestane",{"trials":1473,"activeCount":98},[],{"trials":1475,"activeCount":98},[],{"trials":1477,"activeCount":98},[],{"intervention":1471,"totalTrials":94,"cells":1479},{"EARLY_PHASE1":1480,"PHASE1":1482,"PHASE2":1484,"PHASE3":1490,"PHASE4":1492,"NA":1494},{"trials":1481,"activeCount":98},[],{"trials":1483,"activeCount":98},[],{"trials":1485,"activeCount":98},[1486],{"nctId":1462,"briefTitle":1463,"status":452,"phases":1487,"primaryCompletion":1465,"completion":1466,"start":1467,"enrollment":1468,"conditions":1488,"interventions":1489},[88],[15],[1453,1471],{"trials":1491,"activeCount":98},[],{"trials":1493,"activeCount":98},[],{"trials":1495,"activeCount":98},[],{"intervention":1497,"totalTrials":94,"cells":1498},"Cabazitaxel",{"EARLY_PHASE1":1499,"PHASE1":1501,"PHASE2":1503,"PHASE3":1514,"PHASE4":1516,"NA":1518},{"trials":1500,"activeCount":98},[],{"trials":1502,"activeCount":98},[],{"trials":1504,"activeCount":98},[1505],{"nctId":1506,"briefTitle":1507,"status":141,"phases":1508,"primaryCompletion":726,"completion":1509,"start":1510,"enrollment":98,"conditions":1511,"interventions":1513},"NCT01913067","Evaluation of Cabazitaxel in Patients With Brain Metastasis Secondary to Breast Cancer and NSCLC",[88],"2016-09","2013-09",[1512,15,26],"Brain Metastasis",[1497],{"trials":1515,"activeCount":98},[],{"trials":1517,"activeCount":98},[],{"trials":1519,"activeCount":98},[],{"intervention":1521,"totalTrials":94,"cells":1522},"KADCYLA 160 MG",{"EARLY_PHASE1":1523,"PHASE1":1525,"PHASE2":1527,"PHASE3":1538,"PHASE4":1540,"NA":1542},{"trials":1524,"activeCount":98},[],{"trials":1526,"activeCount":98},[],{"trials":1528,"activeCount":98},[1529],{"nctId":1530,"briefTitle":1531,"status":141,"phases":1532,"primaryCompletion":1533,"completion":1533,"start":1534,"enrollment":98,"conditions":1535,"interventions":1537},"NCT03203616","Kadcyla In pAtients With bRAin Metastasis",[88],"2018-08-27","2018-02-23",[1536],"Metastatic HER2-positive Breast Cancer With Brain Metastasis",[1521],{"trials":1539,"activeCount":98},[],{"trials":1541,"activeCount":98},[],{"trials":1543,"activeCount":98},[],{"intervention":1545,"totalTrials":94,"cells":1546},"Palbociclib",{"EARLY_PHASE1":1547,"PHASE1":1549,"PHASE2":1551,"PHASE3":1564,"PHASE4":1566,"NA":1568},{"trials":1548,"activeCount":98},[],{"trials":1550,"activeCount":98},[],{"trials":1552,"activeCount":98},[1553],{"nctId":1554,"briefTitle":1555,"status":452,"phases":1556,"primaryCompletion":1557,"completion":1558,"start":1559,"enrollment":1560,"conditions":1561,"interventions":1563},"NCT03065621","Neoadjuvant Biomarker ResearcH Study of Palbociclib Combined With Endocrine Therapy in Estrogen Receptor Positive\u002FHER2 Negative Breast CAncer (NeoRHEA)",[88],"2019-03-28","2023-02-01","2017-07-05",100,[1562],"Breast Cancer Female",[1545],{"trials":1565,"activeCount":98},[],{"trials":1567,"activeCount":98},[],{"trials":1569,"activeCount":98},[],{"intervention":147,"totalTrials":94,"cells":1571},{"EARLY_PHASE1":1572,"PHASE1":1574,"PHASE2":1576,"PHASE3":1582,"PHASE4":1584,"NA":1586},{"trials":1573,"activeCount":98},[],{"trials":1575,"activeCount":98},[],{"trials":1577,"activeCount":98},[1578],{"nctId":139,"briefTitle":140,"status":141,"phases":1579,"primaryCompletion":143,"completion":143,"start":144,"enrollment":98,"conditions":1580,"interventions":1581},[88],[15],[147,148],{"trials":1583,"activeCount":98},[],{"trials":1585,"activeCount":98},[],{"trials":1587,"activeCount":98},[],{"intervention":1589,"totalTrials":94,"cells":1590},"GCSF administration on days 8 and 12 after chemotherapy",{"EARLY_PHASE1":1591,"PHASE1":1593,"PHASE2":1595,"PHASE3":1605,"PHASE4":1607,"NA":1609},{"trials":1592,"activeCount":98},[],{"trials":1594,"activeCount":98},[],{"trials":1596,"activeCount":98},[1597],{"nctId":1598,"briefTitle":1599,"status":463,"phases":1600,"primaryCompletion":143,"completion":143,"start":1601,"enrollment":1602,"conditions":1603,"interventions":1604},"NCT01658956","Effectiveness of Reduced GCSF Dosing in Patients With a Low to Moderate Risk of Febrile Neutropenia",[88],"2012-07",142,[15],[1589],{"trials":1606,"activeCount":98},[],{"trials":1608,"activeCount":98},[],{"trials":1610,"activeCount":98},[],{"intervention":1612,"totalTrials":94,"cells":1613},"Checkpoint Blockade, Immune",{"EARLY_PHASE1":1614,"PHASE1":1616,"PHASE2":1618,"PHASE3":1640,"PHASE4":1642,"NA":1644},{"trials":1615,"activeCount":98},[],{"trials":1617,"activeCount":98},[],{"trials":1619,"activeCount":98},[1620],{"nctId":1621,"briefTitle":1622,"status":463,"phases":1623,"primaryCompletion":1624,"completion":1625,"start":1626,"enrollment":1627,"conditions":1628,"interventions":1639},"NCT05429866","Immunological Variables Associated to ICI Toxicity in Cancer Patients",[88],"2024-06-01","2024-12-01","2022-09-01",441,[15,1629,26,1630,1631,21,1632,1633,1634,1635,1636,1637,1638],"Melanoma","Non-melanoma Skin Cancer","Gastrointestinal Cancer","Renal Cell Carcinoma","Small Cell Lung Cancer","Mesothelioma, Malignant","Bladder Cancer","Merkel Cell Carcinoma","Hepatocellular Carcinoma","MSI-H Colorectal Cancer",[1612],{"trials":1641,"activeCount":98},[],{"trials":1643,"activeCount":98},[],{"trials":1645,"activeCount":98},[],{"intervention":1647,"totalTrials":94,"cells":1648},"lapatinib and temozolomide",{"EARLY_PHASE1":1649,"PHASE1":1651,"PHASE2":1663,"PHASE3":1665,"PHASE4":1667,"NA":1669},{"trials":1650,"activeCount":98},[],{"trials":1652,"activeCount":98},[1653],{"nctId":1654,"briefTitle":1655,"status":452,"phases":1656,"primaryCompletion":1657,"completion":1657,"start":1658,"enrollment":11,"conditions":1659,"interventions":1662},"NCT00614978","Lapatinib and Temozolomide for the Treatment of Progressive Brain Disease in HER-2 Positive Breast Cancer",[87],"2011-06","2008-01",[1660,999,1661],"Metastatic Breast Cancer","HER2 Positive",[1647],{"trials":1664,"activeCount":98},[],{"trials":1666,"activeCount":98},[],{"trials":1668,"activeCount":98},[],{"trials":1670,"activeCount":98},[],{"intervention":1672,"totalTrials":94,"cells":1673},"225Ac-DOTATATE",{"EARLY_PHASE1":1674,"PHASE1":1676,"PHASE2":1689,"PHASE3":1691,"PHASE4":1693,"NA":1695},{"trials":1675,"activeCount":98},[],{"trials":1677,"activeCount":98},[1678],{"nctId":1679,"briefTitle":1680,"status":141,"phases":1681,"primaryCompletion":1682,"completion":1682,"start":1683,"enrollment":98,"conditions":1684,"interventions":1688},"NCT06411301","A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors",[87],"2026-10","2024-10",[1685,1686,1687],"Multiple Myeloma, Refractory","Multiple Myeloma in Relapse","Multiple Myeloma Progression",[1672],{"trials":1690,"activeCount":98},[],{"trials":1692,"activeCount":98},[],{"trials":1694,"activeCount":98},[],{"trials":1696,"activeCount":98},[],{"intervention":1698,"totalTrials":94,"cells":1699},"capecitabine",{"EARLY_PHASE1":1700,"PHASE1":1702,"PHASE2":1718,"PHASE3":1720,"PHASE4":1722,"NA":1724},{"trials":1701,"activeCount":98},[],{"trials":1703,"activeCount":98},[1704],{"nctId":1705,"briefTitle":1706,"status":452,"phases":1707,"primaryCompletion":814,"completion":814,"start":1510,"enrollment":791,"conditions":1708,"interventions":1715},"NCT01843725","Phase 1 Study Testing the Combination of Aflibercept and Capecitabine in Metastatic Digestive and Breast Cancers",[87],[1709,1710,1711,1712,1713,1714],"Metastatic Colorectal Cancers","Metastatic Gastric Cancers","Metastatic Oesophageal Cancers","Metastatic Pancreatic Cancers","Metastatic Biliary Cancers","Metastatic Breast Cancers",[1698,1716,1717],"aflibercept","Capecitabine",{"trials":1719,"activeCount":98},[],{"trials":1721,"activeCount":98},[],{"trials":1723,"activeCount":98},[],{"trials":1725,"activeCount":98},[],{"intervention":1716,"totalTrials":94,"cells":1727},{"EARLY_PHASE1":1728,"PHASE1":1730,"PHASE2":1736,"PHASE3":1738,"PHASE4":1740,"NA":1742},{"trials":1729,"activeCount":98},[],{"trials":1731,"activeCount":98},[1732],{"nctId":1705,"briefTitle":1706,"status":452,"phases":1733,"primaryCompletion":814,"completion":814,"start":1510,"enrollment":791,"conditions":1734,"interventions":1735},[87],[1709,1710,1711,1712,1713,1714],[1698,1716,1717],{"trials":1737,"activeCount":98},[],{"trials":1739,"activeCount":98},[],{"trials":1741,"activeCount":98},[],{"trials":1743,"activeCount":98},[],{"intervention":1745,"totalTrials":94,"cells":1746},"Zr89-trastuzumab",{"EARLY_PHASE1":1747,"PHASE1":1749,"PHASE2":1761,"PHASE3":1763,"PHASE4":1765,"NA":1767},{"trials":1748,"activeCount":98},[],{"trials":1750,"activeCount":98},[1751],{"nctId":1752,"briefTitle":1753,"status":452,"phases":1754,"primaryCompletion":1755,"completion":1755,"start":1756,"enrollment":424,"conditions":1757,"interventions":1760},"NCT01420146","Pilot Imaging Study With 89Zr-Trastuzumab in HER2-positive Metastatic Breast Cancer Patients",[87],"2015-09","2011-08",[1444,1758,1759],"Secondary","HER2 Positive Carcinoma of Breast",[1745],{"trials":1762,"activeCount":98},[],{"trials":1764,"activeCount":98},[],{"trials":1766,"activeCount":98},[],{"trials":1768,"activeCount":98},[],{"intervention":1770,"totalTrials":94,"cells":1771},"Combination of trastuzumab and PS-341",{"EARLY_PHASE1":1772,"PHASE1":1774,"PHASE2":1786,"PHASE3":1788,"PHASE4":1790,"NA":1792},{"trials":1773,"activeCount":98},[],{"trials":1775,"activeCount":98},[1776],{"nctId":1777,"briefTitle":1778,"status":452,"phases":1779,"primaryCompletion":1780,"completion":1780,"start":1781,"enrollment":1782,"conditions":1783,"interventions":1785},"NCT00199212","PS-341 in Combination With Herceptin in Advanced Breast Cancer That Overexpresses HER-2",[87],"2007-12","2003-10",19,[1784],"Carcinoma Breast Stage IV",[1770],{"trials":1787,"activeCount":98},[],{"trials":1789,"activeCount":98},[],{"trials":1791,"activeCount":98},[],{"trials":1793,"activeCount":98},[],{"intervention":1795,"totalTrials":29,"cells":1796},"chemotherapy",{"EARLY_PHASE1":1797,"PHASE1":1799,"PHASE2":1801,"PHASE3":1812,"PHASE4":1814,"NA":1816},{"trials":1798,"activeCount":98},[],{"trials":1800,"activeCount":98},[],{"trials":1802,"activeCount":98},[1803],{"nctId":1804,"briefTitle":1805,"status":452,"phases":1806,"primaryCompletion":1807,"completion":1807,"start":1808,"enrollment":1809,"conditions":1810,"interventions":1811},"NCT01290926","Sorafenib Plus Capecitabine Efficacy Assessment in Patients With Advanced Pre-treated Colorectal Cancer",[88],"2016-01","2011-02",97,[18],[1795],{"trials":1813,"activeCount":98},[],{"trials":1815,"activeCount":98},[],{"trials":1817,"activeCount":98},[1818],{"nctId":1819,"briefTitle":1820,"status":463,"phases":1821,"start":1822,"enrollment":1823,"conditions":1824,"interventions":1826},"NCT00398437","Magnetic Resonance Imaging for the Early Detection of CNS Metastases in Women With Stage IV Breast Cancer",[91],"2006-09",96,[15,1825],"Metastatic Cancer",[1827,1795],"trastuzumab",{"intervention":1827,"totalTrials":94,"cells":1829},{"EARLY_PHASE1":1830,"PHASE1":1832,"PHASE2":1834,"PHASE3":1836,"PHASE4":1838,"NA":1840},{"trials":1831,"activeCount":98},[],{"trials":1833,"activeCount":98},[],{"trials":1835,"activeCount":98},[],{"trials":1837,"activeCount":98},[],{"trials":1839,"activeCount":98},[],{"trials":1841,"activeCount":98},[1842],{"nctId":1819,"briefTitle":1820,"status":463,"phases":1843,"start":1822,"enrollment":1823,"conditions":1844,"interventions":1845},[91],[15,1825],[1827,1795],{"intervention":1847,"totalTrials":94,"cells":1848},"FOLFOX",{"EARLY_PHASE1":1849,"PHASE1":1851,"PHASE2":1853,"PHASE3":1855,"PHASE4":1857,"NA":1859},{"trials":1850,"activeCount":98},[],{"trials":1852,"activeCount":98},[],{"trials":1854,"activeCount":98},[],{"trials":1856,"activeCount":98},[],{"trials":1858,"activeCount":98},[],{"trials":1860,"activeCount":98},[1861],{"nctId":1862,"briefTitle":1863,"status":452,"phases":1864,"primaryCompletion":1417,"completion":1417,"start":1865,"enrollment":1866,"conditions":1867,"interventions":1869},"NCT00994864","Preoperative Chemosensitivity Testing to Predict Treatment Benefit in Adjuvant Stage III Colon Cancer",[91],"2009-11",235,[1868],"Colon Cancer",[1847]]